Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.>> Learn more…
ChinaBio In the News
"Mr. Bio in China"
The Week in Review: Jinhe Biotech Stages $79 Million IPO in Shenzhen
Deals and Financings
Jinhe Biotechnology (SHE: 002688), located in Inner Mongolia, raised $78.6 million in an IPO on the Shenzhen Small and Medium exchange (see story). The company placed 27 million A shares of common stock at a price of 18 RMB each, according to filings. Jinhe makes antibiotics that are administered to livestock as feed additives. In 2011, the company reported operating income of $113 million and net profit of $12 million.
Tianjin International Joint Academy of Biotechnology and Medicine (TJAB) formed a JV with Antisense Therapeutics (ASX: ANP) of Australia to develop a drug discovered by ANP (see story). The drug, ATL1102, is aimed at multiple sclerosis, stem cell mobilization and asthma. TJAB will be responsible for marketing in China and Hong Kong, while ANP will retain those duties for the rest of the world.
Lee’s Pharmaceutical (HK: 950) of Hong Kong bought the China rights to a novel clinical-stage peptide from RegeneRx Biopharma (OTCBB: RGRX) (see story). Thymosin beta 4 (Tβ4) is being developed by for tissue and organ protection, repair and regeneration. Its three formulations target very different indications: dry eye, cardiovascular/nervous system disorders, and skin disease/chronic wounds.
Chengdu Hoist (SHE: 000790) is getting out of the veterinary biological business (see story). The company said the animal health segment no longer made economic sense due to rising labor and raw material costs. In 2011, animal health produced about 11 million RMB ($1.7 million) of revenue and 2.4 million RMB ($387,000) of cash flow for Chengdu Hoist. In addition to its building construction activities, Chengdu Hoist makes TCM and Western drugs, including biological products.
The Wuhan Institute of Biological Products (WIBF) formed a collaboration with Refine Technology, a US maker of biological manufacturing equipment (see story). WIBF is a division of China National Biological Group, a Sinopharm subsidiary. WIPF and Refine will use Refine’s ATF™ System, a cell retention device, to improve the yield and reduce the cost of vaccine manufacturing. The collaboration will work on a specific novel vaccine, which was not identified.
China Health Resource (OTCBB: CHRI) announced a new TCM migraine medication, built around the company’s major product, Dahurian Angelica (DAR) root (see story). According to the company, the product showed an effective rate of 96.5% in clinical observations, though the conditions of the test were not disclosed. China Health Resource produces raw DAR and finished products based on the TCM.
Trials and Approvals
Shanghai Jia Fu Medical Apparatus Inc. completed the dosing of two patients with an experimental stem cell treatment developed by MediStem (PinkSheets: MEDS) of the US (see story). Endometrial Regenerative Cell (ERC) is a universal donor stem cell product collected from the uterus. It was administered as an intramuscular injection to two patients with critical limb ischemia as part of a 15-patient study. Neither patient showed any signs of adverse effects.
Ironwood Pharmaceuticals (NSDQ: IRWD) has filed a Clinical Trial Application with the SFDA for a China Phase III trial of linaclotide (see story). Linaclotide is a peptide agonist aimed at treating abdominal pain in patients with irritable bowel syndrome accompanied by constipation. Ironwood, a Massachusetts pharma, still owns the China rights to the drug, although it has partnered linaclotide for much of the rest of the world.
ChinaBio® Partnering Forum 2013
May 29-30, 2013
China Medical Affairs Summit
June 18-19, 2013